Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mochida Pharmaceutical Co., Ltd. (4534:JPX), powered by AI.
Mochida Pharmaceutical Co., Ltd. is currently trading at ¥3,150. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Mochida Pharmaceutical Co., Ltd. on Alpha Lenz.
Mochida Pharmaceutical Co., Ltd.'s P/E ratio is 19.6.
“Mochida Pharmaceutical Co., Ltd. trades at a P/E of 19.6 (fair value) with modest ROE of 4.4%.”
Ask for details →Mochida Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, focused on the research, development, and manufacturing of a diverse range of medical products. Primarily, the company engages in creating prescription drugs, covering therapeutic areas such as oncology, cardiology, and dermatology, which are critical for patient treatments worldwide. Additionally, it extends its expertise into over-the-counter medications, diagnostic agents, and healthcare products. A notable feature of Mochida Pharmaceutical is its emphasis on R&D, reflected in its development of innovative therapies aimed at addressing unmet medical needs. Within the financial market, Mochida Pharmaceutical holds significance as a key player in Japan's robust healthcare sector. As a steadfast contributor to the pharmaceutical landscape, the company supports global health advancement through strategic partnerships and collaborations, driving forward medical science and patient care.
“Mochida Pharmaceutical Co., Ltd. trades at a P/E of 19.6 (fair value) with modest ROE of 4.4%.”
Ask for details →Mochida Pharmaceutical Co., Ltd. (ticker: 4534) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,508 employees. Market cap is $111.7B.
The current price is 3,150 with a P/E ratio of 19.64x and P/B of 0.85x.
ROE is 4.40% and operating margin is 7.73%. Annual revenue is $105.2B.